IMGN News and Press, ImmunoGen Inc. From 04/27/23

2023-04-27 15:09:37 ET The stock market’s current volatility may have piqued your interest in investing in penny stocks . Usually priced below $5, these stocks are known for their significant price fluctuations and potential for high returns, albeit with considerable risks. In th...

2023-04-27 11:00:33 ET ImmunoGen ( NASDAQ: IMGN ) is scheduled to announce Q1 earnings results on Friday, April 28th, before market open. The consensus EPS Estimate is -$0.25 and the consensus Revenue Estimate is $21.63M (-43.2% Y/Y). Over the last 2 years, IMGN has ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer. "We are excited to welcome Isabel to ImmunoGen's Execu...

2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results. Management w...

2023-04-06 06:47:17 ET ImmunoGen ( NASDAQ: IMGN ) signed a term loan financing facility for up to $175M with entities managed by Pharmakon Advisors. The company said the funds will strengthen its balance sheet and provide additional capital to support growth. Und...

ImmunoGen to Receive $75 Million Upon Execution of the Agreement; Eligible to Receive up to an Additional $100 Million in Near-Term Proceeds ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announce...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate r...

ImmunoGen, Inc. (IMGN) Q4 2022 Earnings Conference Call March 01, 2023, 08:00 AM ET Company Participants Anabel Chan - Head, IR Mark Enyedy - President and CEO Anna Berkenblit - Chief Medical Officer Renee Lentini - Interim-CFO Todd Talarico - Interim-Chief Com...

ImmunoGen press release ( NASDAQ: IMGN ): Q4 GAAP EPS of -$0.23 beats by $0.07 . Revenue of $41.2M (+47.1% Y/Y) beats by $24.02M . ImmunoGen had $275.1 million in cash and cash equivalents as of December 31, 2022, compared with $478.8 million as of December 31, 2021. ...